M&A / Deals Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B BioSpaceWhile peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule approach.M&A / DealsMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioSpace While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule approach. M&A / DealsMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA Ties Amgen’s Rare Inflammatory Disease Drug to Eight Deaths, Dozens of Liver InjuriesNext: Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
